PL2575872T3 - Zatężanie antygenów szczepionkowych grypy bez liofilizacji - Google Patents

Zatężanie antygenów szczepionkowych grypy bez liofilizacji

Info

Publication number
PL2575872T3
PL2575872T3 PL11743338.3T PL11743338T PL2575872T3 PL 2575872 T3 PL2575872 T3 PL 2575872T3 PL 11743338 T PL11743338 T PL 11743338T PL 2575872 T3 PL2575872 T3 PL 2575872T3
Authority
PL
Poland
Prior art keywords
lyophilization
concentration
influenza vaccine
vaccine antigens
antigens
Prior art date
Application number
PL11743338.3T
Other languages
English (en)
Inventor
Sushma Kommareddy
Amanda Scampini
Barbara Baudner
Derek O'hagan
Manmohan Singh
Original Assignee
Seqirus UK Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seqirus UK Limited filed Critical Seqirus UK Limited
Publication of PL2575872T3 publication Critical patent/PL2575872T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Surgical Instruments (AREA)
PL11743338.3T 2010-06-01 2011-06-01 Zatężanie antygenów szczepionkowych grypy bez liofilizacji PL2575872T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39671910P 2010-06-01 2010-06-01
US201161465405P 2011-03-18 2011-03-18
PCT/IB2011/001542 WO2011151723A2 (en) 2010-06-01 2011-06-01 Concentration of vaccine antigens without lyophilization

Publications (1)

Publication Number Publication Date
PL2575872T3 true PL2575872T3 (pl) 2021-02-22

Family

ID=45067143

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11743338.3T PL2575872T3 (pl) 2010-06-01 2011-06-01 Zatężanie antygenów szczepionkowych grypy bez liofilizacji

Country Status (15)

Country Link
US (1) US20130224245A1 (pl)
EP (2) EP3827843B1 (pl)
JP (1) JP5959508B2 (pl)
KR (5) KR20220163497A (pl)
CN (1) CN103096921A (pl)
AU (1) AU2011262309B2 (pl)
BR (1) BR112012030619A2 (pl)
CA (1) CA2801149A1 (pl)
DK (1) DK2575872T3 (pl)
EA (1) EA201291437A1 (pl)
ES (2) ES3075679T3 (pl)
HU (1) HUE051711T2 (pl)
PL (1) PL2575872T3 (pl)
PT (1) PT2575872T (pl)
WO (1) WO2011151723A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2808965C (en) 2010-08-20 2020-01-07 Theraject, Inc. Soluble needle arrays for delivery of influenza vaccines
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
AU2016290603B2 (en) * 2015-07-07 2022-06-02 Seqirus UK Limited Influenza potency assays
US11628208B2 (en) * 2015-10-05 2023-04-18 The Corporation Of Mercer University System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins
WO2017062463A1 (en) * 2015-10-05 2017-04-13 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
CA3020634C (en) * 2016-04-14 2025-06-17 Genzyme Corporation MULTIDOSE COMPOSITIONS CONTAINING AN ANTIMICROBIAL PRESERVATIVE BASED ON POLYAMIDE OR OCTENIDINE
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
WO2020056191A1 (en) 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
CN113423381A (zh) * 2018-12-03 2021-09-21 艾里奥治疗公司 大药剂的改进递送
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
US20240382183A1 (en) * 2023-05-15 2024-11-21 William Marsh Rice University Rapid sampling of interstitial fluid using a microneedle array and vaccum-assisted skin patch
KR20250171641A (ko) 2024-05-30 2025-12-09 경희대학교 산학협력단 구강 용해 필름 제형의 바이러스 백신 조성물

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
DE69229114T2 (de) 1991-03-01 1999-11-04 Minnesota Mining And Mfg. Co., Saint Paul 1,2-substituierte 1h-imidazo[4,5-c]chinolin-4-amine
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
JPH09511381A (ja) 1994-01-11 1997-11-18 ブラームス・インターユニバージテーア・インスティテュート・ボーア・ビーオテクノロジー インフルエンザワクチン
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
WO1998046262A1 (en) 1997-04-16 1998-10-22 Connaught Laboratories, Inc. Anti-influenza compositions supplemented with neuraminidase
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
PL355287A1 (pl) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Donosowa szczepionka przeciw wirusowi grypy
CA2401117C (en) 2000-03-03 2010-06-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US7803392B2 (en) 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
EP1361890B1 (en) 2001-02-23 2011-03-30 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
WO2003004341A1 (fr) 2001-06-30 2003-01-16 Haiyue Zhang Bicyclette multifonction permettant de faire de l'exercice et de la gymnastique
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
TW200409657A (en) * 2002-08-08 2004-06-16 Alza Corp Transdermal vaccine delivery device having coated microprotrusions
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
CN101124343A (zh) * 2004-04-01 2008-02-13 阿尔扎公司 用于经皮肤输送流感疫苗的装置和方法
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
US20050266011A1 (en) * 2004-05-19 2005-12-01 Yuh-Fun Maa Method and formulation for transdermal delivery of immunologically active agents
AU2005245943A1 (en) 2004-05-20 2005-12-01 Id Biomedical Corporation Process for the production of an influenza vaccine
RS51665B (sr) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Smanjenje potencijalnih jatrogenih rizika povezanih sa vakcinama protiv gripa
ES2526170T3 (es) 2004-12-23 2015-01-07 Medimmune, Llc Línea celular MDCK no tumorigénica para propagar virus
ATE412737T1 (de) * 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
CN101687094B (zh) 2005-09-06 2012-09-26 谢拉杰克特股份有限公司 含有药物颗粒和/或药物吸附颗粒的固体溶液穿孔器
ATE494906T1 (de) 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
WO2007061781A1 (en) 2005-11-18 2007-05-31 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
WO2007059289A1 (en) 2005-11-18 2007-05-24 3M Innovative Properties Company Microneedle arrays and methods of preparing same
WO2007124393A2 (en) 2006-04-20 2007-11-01 3M Innovative Properties Company Molded articles comprising microneedle arrays
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
WO2008152052A1 (en) * 2007-06-14 2008-12-18 Berna Biotech Ag Intradermal influenza vaccine
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
WO2010002418A2 (en) 2008-07-01 2010-01-07 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
MX2011002688A (es) * 2008-09-12 2011-04-12 Critical Pharmaceuticals Ltd Mejoramientos en la absorcion de agentes terapeuticos a traves de las membranas mucosas o la piel.
KR20110074563A (ko) * 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법

Also Published As

Publication number Publication date
CN103096921A (zh) 2013-05-08
PT2575872T (pt) 2020-11-19
KR20180096829A (ko) 2018-08-29
EA201291437A1 (ru) 2013-05-30
HUE051711T2 (hu) 2021-03-29
KR102471356B1 (ko) 2022-11-28
JP2013534912A (ja) 2013-09-09
KR20130109004A (ko) 2013-10-07
US20130224245A1 (en) 2013-08-29
AU2011262309A1 (en) 2012-12-20
KR20200057097A (ko) 2020-05-25
CA2801149A1 (en) 2011-12-08
KR20220163497A (ko) 2022-12-09
JP5959508B2 (ja) 2016-08-02
KR102113512B1 (ko) 2020-05-22
ES3075679T3 (en) 2026-08-06
EP2575872B1 (en) 2020-08-19
AU2011262309B2 (en) 2015-08-13
KR20210154996A (ko) 2021-12-21
EP3827843A1 (en) 2021-06-02
WO2011151723A3 (en) 2012-06-07
DK2575872T3 (da) 2020-10-19
ES2825712T3 (es) 2021-05-17
BR112012030619A2 (pt) 2019-09-24
EP3827843C0 (en) 2026-05-20
WO2011151723A2 (en) 2011-12-08
EP2575872A2 (en) 2013-04-10
EP3827843B1 (en) 2026-05-20

Similar Documents

Publication Publication Date Title
PT2575872T (pt) Concentração de antigénios da vacina da gripe sem liofilização
PL2575873T3 (pl) Zatężanie i liofilizacja antygenów szczepionkowych grypy
IL262123A (en) Influenza virus vaccines and uses thereof
IL261204A (en) Influenza virus vaccines and their use
ZA201404797B (en) Influenza virus vaccines and uses thereof
IL248607A (en) Methods and compositions for immunization against virus
EP2552479A4 (en) INFLUENZA VIRUS VACCINES AND USES THEREOF
DK3170508T3 (da) Vaccineformuleringer
EP2595653A4 (en) INFLUENZA VACCINE
EP2753345A4 (en) POLYPEPTIDIMPFSTOFF
IL229307A0 (en) Inactivated dengue virus vaccine
HUE044772T2 (hu) Immunogén készítmény
EP2755680A4 (en) PARTICULATE VACCINE FORMULATIONS
HUE046858T2 (hu) Vakcina és eljárások campylobacter fertõzés csökkentésére
EP2852396A4 (en) INFLUENZA VACCINE CONSTRUCTS
IL224022B (en) Thermally stable influenza vaccine
IL231043A0 (en) vaccine
SMT201700046B (it) Micobatterio ricombinante come vaccino
IL232172A0 (en) Antigen presenting cancer vaccine
EP2588135A4 (en) Nanoemulsion vaccines
EP2771350A4 (en) TOPK PEPTIDES AND VACCINES CONTAINING THEM
EP2543387A4 (en) MUCOSA VACCINE
EP2919806A4 (en) MTON PEPTIDES AND VACCINES DERIVED FROM GONOCOCCES
EP2763699A4 (en) VACCINE
EP2667891A4 (en) COMBINATION VACCINES